Nevertheless, the effectual clinical benefits of checkpoint blockade are hampered by a high rate of primary drug-resistance, where only a small proportion of recipients respond to the therapy, suggesting that larvaceous reversal of host immunity by PD-L1/PD-1 blockade might hinge on the abundance of CD8+ TILs infiltrated in the tumor microenvironment. The gene discussed is CD8A; the disease is neoplasm.